Skip to content
Article Rich – Lifestyle
Author:
J. Law Stock Limited
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
June 15, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 7, 2026
J Law Sets Two-Year Record With 1,499% Return in U.S. Investing Championship
March 5, 2026